W2O symplur

News

W2O has chalked up its fifth acquisition in less than a year with a deal to buy healthcare social media analytics company Symplur.

News

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.